Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;44(4):1061-1070.
doi: 10.1111/liv.15852. Epub 2024 Feb 2.

Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa

Zobair M Younossi  1   2 , Pegah Golabi  1   2 , James Paik  1   2 , Soroor Owrangi  2 , Yusuf Yilmaz  1   3 , Mohamed El-Kassas  1   4 , Khalid Alswat  1   5 , Saleh A Alqahtani  1   6   7
Affiliations

Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa

Zobair M Younossi et al. Liver Int. 2024 Apr.

Abstract

Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed the prevalence of NAFLD/MASLD in the general population and among patients with T2D in the Middle East and North Africa (MENA) region.

Methods: We searched PubMed and Embase for English-language articles published between 1990 and 2023 according to PRISMA. Each country's NAFLD/MASLD prevalence in the general population and in T2D patients was predicted by using a multivariable meta regression model. Input data were extracted from our systematic review, GBD and NCD Risk Factor Collaboration. Confidence intervals were constructed by using prediction intervals with the delta method.

Results: Meta-analytic pooling estimated the prevalence of NAFLD/MASLD as 39.43% in the general population and 68.71% among T2D patients. NAFLD/MASLD prevalence has increased from 35.42% (2008-2016) to 46.20% (2017-2020). Using GBD-2019 dataset, it was predicted that there are 141.51 million cases of NAFLD/MASLD in the MENA region. The highest number of NAFLD/MASLD cases were expected in Egypt (25.71 million), followed by Türkiye (23.33 million) and Iran (19.85 million). Estimated NAFLD prevalence exceeded 40% in 10 of 21 countries with the top countries being Kuwait (45.37%), Egypt (45.0%), Qatar (44.4%), and Jordan (43.3%). Furthermore, it was predicted that there are 24.96 million cases of NAFLD/MASLD with T2D in the MENA region.

Conclusions: In the MENA region, prevalence of NAFLD/MASLD is very high and growing, necessitating an urgent need for regional public policy to deal with this growing burden.

Keywords: MASH; MASLD; MENA; Middle East; NAFLD; NASH; North Africa; T2D; steatotic liver disease.

PubMed Disclaimer

References

REFERENCES

    1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335‐1347. doi:10.1097/HEP.0000000000000004
    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multi‐society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542‐1556. doi:10.1016/j.jhep.2023.06.003
    1. En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non‐alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta‐analysis. Gut. 2023;72:2138‐2148. doi:10.1136/gutjnl-2023-330110
    1. Younossi Z, Golabi P, Price JK, et al. A rapid rise in the global prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Presented at American Association for the Study of Liver Diseases (AASLD), Boston, MA, USA, November 10‐14, 2023, p. s911. doi:10.1097/HEP.0000000000000580
    1. Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56:942‐956. doi:10.1111/apt.17158

Publication types

MeSH terms